causalStudio™ Login
Solutions
Unique Data
Registries
TARGET-LIVER DISEASE
TARGET-GASTRO
TARGET-DERM
TARGET-NASH
TARGET-IBD
TARGET-HCC
TARGET-PBC
TARGET-HBV
Precision Medicine
Advanced Analytics
Custom Analytics
Innovative Technology
causalStudio™
engage™
Research
News
Publications
Partnerships
Events
2025
ISPE 2025
EASL 2025
ISPOR 2025
DDW 2025
AAD 2025
2024
The Liver Meeting 2024
About
Company Overview
Company Timeline
Team
Careers
Contact Us
causalStudio™ Login
News & Articles
6/24/2025
Target RWE Advances Next-Generation Causal Inference Approaches in Real-World Evidence with New Publications
Read More
6/9/2025
DDG 2025 Research: Presentation by Michael Roden, MD
Read More
5/9/2025
Target RWE at EASL 2025: Advancing HCC, MASH & PBC Research
Read More
5/8/2025
EASL 2025 Research: Presentation by Michael Roden, MD
Read More
5/5/2025
Ed Seguine Appointed CEO of Target RWE
Read More
4/25/2025
How does causalStudio™ address the key regulatory requirements for data integrity, traceability, and analysis?
Read More
4/3/2025
An Overview of MASH: Advancements in Diagnosis, Treatment, and the Role of Real-World Data
Read More
3/31/2025
Addressing the Burden of Hidradenitis Suppurativa: The Often-Hidden Impact on Quality of Life
Read More
3/18/2025
AASLD Opens Call for Applications for Sites to Participate in TARGET-LD and the Cirrhosis Quality Collaborative (CQC Data Registry)
Read More
3/7/2025
Patient-Centric Data Capture Fuels Growth of Target RWE Longitudinal, Real-World Dermatology Studies
Read More
2/20/2025
Causal Inference for Regulatory-Grade Evidence Generation: Behind the Data
Read More
1/31/2025
Maximizing the Value of Real-World Data: The Critical Role of Causal Inference in Pharmaceutical Innovation
Read More
1/7/2025
Highlander Health Announces Inaugural Investment of Target RWE
Read More
12/11/2024
New Patient-Reported Outcome Insights from Target RWE: NASH-CHECK Reveals Stability Over Time and Worse Scores Among Those with Decompensated Cirrhosis of Patients with MASLD
Read More
12/4/2024
The Liver Meeting 2024 Research: Cirrhosis Presentation by Arun J. Sanyal, MBBS, MD
Read More
12/4/2024
The Liver Meeting 2024 Research: NASH-CHECK Presentation by Arun J. Sanyal, MBBS, MD
Read More
12/4/2024
The Liver Meeting 2024 Research: Presentation by A. Sidney Barritt IV, MD, MSCR
Read More
12/4/2024
ACG 2024 Research: Presentation by A. Sidney Barritt IV, MD, MSCR
Read More
12/4/2024
ACG 2024 Research: Presentation by Evan S. Dellon, MD, MPH
Read More
12/3/2024
Target RWE Highlights GLP-1 Receptor Agonists in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease at The Liver Meeting 2024
Read More
11/26/2024
ACG 2024: Target RWE Presents Key MASH and EGIDs Data from Leading Liver Disease & Gastroenterology Real-World Registries
Read More
11/25/2024
New Target RWE Research Validates Updated Liver Disease Terminology in Children
Read More
11/18/2024
Target RWE Unveils Latest Developments in TARGET-Liver Disease and Cirrhosis Quality Collaborative Partnership with the American Association for the Study of Liver Diseases
Read More
10/29/2024
DIA RWE 2024 Research: Presentation by Nuvan Rathnayaka
Read More
10/29/2024
DIA RWE 2024 Research: Presentation by David Pritchard, PhD
Read More
10/28/2024
New Research and Methodological Innovations Presented by Target RWE at DIA RWE 2024
Read More
10/24/2024
Transforming Healthcare Through Data: Ewa J. Kleczyk on Precision Medicine, Diversity, and AI Challenges
Read More
10/9/2024
Advancing RWE: Target RWE's Staging and Clean Room Committee Approaches Set New Benchmark
Read More
8/27/2024
ISPE 2024 Research: Presentation by Kathleen Hurwitz ScD, Catherine Wiener, and Chase Latour
Read More
8/21/2024
Target RWE Announces the Launch of engage™ - An Innovative, Digital Patient-Centric Engagement Platform
Read More
8/21/2024
Sequential Nested Trial Emulation Presented by Real-World Evidence Leader Target RWE at ISPE 2024
Read More
6/12/2024
Real World TARGET-NASH Analysis Shows High Concordance Between New MASLD Definitions and Prior TARGET-NASH Pragmatic Definitions
Read More
6/11/2024
EASL 2024 Research: Presentation by Arun J. Sanyal, MBBS, MD
Read More
6/11/2024
EASL 2024 Research: Presentation by A. Sidney Barritt IV, MD, MSCR
Read More
6/11/2024
GLP-1 Use and NASH-CHECK Patient-Reported Outcomes Studies from Target RWE Presented at EASL 2024
Read More
6/4/2024
World’s Largest Liver Disease-Focused Registry Surpasses 400,000 Patient Enrollment Milestone
Read More
5/17/2024
Real-World Evidence Leader in Inflammatory Bowel Disease, Target RWE, Announces Expanded Footprint with TARGET-GASTRO Registry of 30,000+ Patients At Digestive Disease Week
Read More
4/15/2024
AGA Announces New Partnership with Target RWE to Gather Real World Data on Eosinophilic Esophagitis (EoE)
Read More
3/8/2024
Patient-Reported Outcomes Data from Longest Running Dermatology Study: TARGET-DERM AA Poster Presented at American Academy of Dermatology (AAD) 2024
Read More
1/4/2024
Target RWE Launches Novel Precision Medicine Platform to Undertake Growing Unmet Medical Needs in Liver Disease, Gastroenterology, and Immune-mediated Inflammatory Conditions
Read More
12/4/2023
Overcoming Scalability Challenges in Real-World Data Processing for Transformative Patient Care
Read More
11/13/2023
Real-World Evidence in Pharmaceutical Drug Development – Faster, Safer and More Relevant?
Read More
11/13/2023
TARGET-NASH Offers Unprecedented Glimpse into Growing Public Health Concerns with Few Treatment Options
Read More
11/10/2023
Target RWE Releases Important Updates on the Cirrhosis Quality Collaborative/TARGET-Liver Disease Partnership with the American Association for the Study of Liver Diseases
Read More
10/23/2023
Leveraging Real-World Evidence with Analytics: 3 Essential Components to Capture a 360-Degree View of Your Patient Population
Read More
9/21/2023
New Eosinophilic Gastrointestinal Disorders (EGIDs) Real World Registry Surpasses 1,000 Patient Milestone
Read More
8/23/2023
Target RWE's Cutting-Edge Analytical Solutions Launched to Propel Real-World Evidence Generation
Read More
8/22/2023
Target RWE Strengthens Industry Leadership Position with Novel Real World Evidence Approaches Presented at ICPE 2023
Read More
6/21/2023
World-Leading Real World Data Registry, TARGET-NASH, Surpasses 7,000+ Enrolled Patients and 500,000+ Months of Patient Follow-Up
Read More
6/2/2023
Event Recap Blog: TARGET-NASH Analysis Presented at ISPOR 2023 and Target RWE Leaders Present at PMSA 2023
Read More
5/8/2023
Real World Evidence Leader Target RWE Shares Expansion and Update on TARGET-GASTRO Longitudinal Study During Digestive Disease Week 2023
Read More
3/30/2023
Validation of a Pragmatic Clinical Risk-Based Classification of NASH - New Supporting Real World Evidence from TARGET-NASH
Read More
3/8/2023
Ewa Kleczyk, PhD Featured on CIO Views Cover for March – A Memento to Women’s History Month & International Women’s Day
Read More
2/28/2023
Longest Running Real World Dermatology Registry, TARGET-DERM, Offers Deep Insight into Complex Diseases
Read More
1/11/2023
Target RWE Launches 35 New Disease State Registries in Complex Indications with High Unmet Medical Needs and Rapidly Evolving Therapies
Read More
10/18/2022
Target RWE and the American Association for the Study of Liver Diseases Announce Research Agreement for Cirrhosis Quality Collaborative
Read More
8/25/2022
New Approaches for Developing Real-World Evidence Presented by Target RWE at the 2022 International Conference on Pharmacoepidemiology (ICPE)
Read More
8/24/2022
Durham-Based Target RWE Grows Data Abstraction, Curation Capabilities with Latest Acquisition
Read More
8/23/2022
Target RWE New Brand, Research, and Advanced Real World Evidence Analytics Showcased at International Conference on Pharmacoepidemiology (ICPE) 2022
Read More
7/20/2022
Real-World Data Finds High Prevalence of Pruritus (Itching) and Fatigue, Low Levels of Treatment in Primary Biliary Cholangitis Population
Read More
6/24/2022
Nonalcoholic Fatty Liver Disease (NAFLD) Research from Target RWE's Real-World Study Presented at International Liver Congress 2022
Read More
6/17/2022
Target RWE Leads Industry Discussion of Fusion Designs and Teaching Advanced Epidemiologic Methods at SER 2022
Read More
6/10/2022
Blog - 5 Ways to Write Better Code Using the Tenets of Functional Programming
Read More
5/22/2022
New Data Presented at DDW 2022 Shows Nearly Two-Fold Risk of Loss of Remission in Ulcerative Colitis Patients Who Had Histologic Inflammation on Baseline Biopsy
Read More
5/20/2022
Target RWE’s Allison Chandler Named One of Triangle Business Journal’s “40 Under 40”
Read More
4/5/2022
Blog - What’s the risk? Impacts of Parametric Assumptions for Causal Analysis of Time-to-event Outcomes
Read More
4/4/2022
Target RWE Primary Biliary Cholangitis (PBC) Encore Data Presented at APASL 2022
Read More
3/29/2022
Large Real-World Study Uncovers Higher Prevalence of Non-Alcoholic Fatty Liver Disease Markers, Liver Biopsy, and Cirrhosis in Children
Read More
3/8/2022
TARGET-IBD Study Reveals Nearly a Third of Patients with Inflammatory Bowel Disease Did Not Undergo Objective Assessment Prior to Biologic Dose Change, Discontinuation
Read More
12/15/2021
Target RWE Dermatology Study Data Shared at 3rd Annual RAD Conference
Read More
11/30/2021
Target RWE Appoints Derek Evans as President
Read More
11/3/2021
Peer-Reviewed Target RWE Study Finds Wide Variance in Nonalcoholic Steatohepatitis (NASH) Pathology Reporting
Read More
10/19/2021
Blog - One Model to Rule Them All: Using a Single Model to Control for Confounding and Informative Censoring
Read More
10/11/2021
Target RWE Inflammatory Bowel Disease Research Presented at UEG Week 2021
Read More
9/13/2021
Update from Paris NASH 2021: New Target RWE Nonalcoholic Steatohepatitis (NASH) Data Presented at This Year’s Meeting
Read More
7/1/2021
Target RWE HBV Research on Antiviral Treatments, Characteristics, and Clinical Outcomes Published in Digestive Diseases and Sciences
Read More
6/29/2021
Liver International Publishes Hepatocellular Carcinoma RWE Review
Read More
6/22/2021
Target RWE Study Shows Significant Differences in Medication Use Among Older Patients with IBD Compared to Younger Patients
Read More
6/15/2021
TARGET-NASH Study Finds Statins Underutilized in Patients with NAFLD and At-Risk of Heart Disease
Read More
5/25/2021
Target RWE COVID-19 Data: Real-World Evidence Analysis Shows 3.6% of COVID-19 Hospitalized Patients Discharged Alive Required Readmission
Read More
5/23/2021
Target RWE Research Presented at DDW 2021 Shows High Rates of Biologic Combination Therapy and Previous Biologic Exposure in IBD Population
Read More
5/13/2021
Crohn’s & Colitis 360 Publishes Target RWE Inflammatory Bowel Disease Data
Read More
3/1/2021
Andrew von Eschenbach, M.D. Joins Target RWE as Senior Advisor
Read More
2/22/2021
TARGET-NASH Real-World Study Reveals Two Thirds Of Patients With NAFLD Had No Record Of Liver Biopsy
Read More
2/2/2021
Target RWE Shares Weight Loss Data From Ongoing NASH Study
Read More
1/15/2021
Target RWE Acquires NoviSci Inc., Adding Significant Analytical Capabilities to Leading Real-World Evidence Platform
Read More
12/21/2020
TARGET-HCC Initial Manuscript Published in Hepatology Communications
Read More
12/18/2020
Target RWE Virtual Posters at Annual AIBD, RAD Conferences
Read More
11/28/2020
TARGET-DERM Objectives Published in BMJ Open
Read More
11/13/2020
Target RWE Data Presented at AASLD Virtual Meeting Provides Important Updates for NASH and PBC Communities
Read More
10/1/2020
TARGET-DERM Real-World Study Success Leads To Global Site Expansion And New Dermatologic Conditions
Read More
9/24/2020
TARGET-NASH Data Publication Finds Nearly One In Five Patients With NAFLD Have Prior Prescription Opioid Use
Read More
9/9/2020
Asian Lean Patients With NAFLD Are 53% Less Likely To Have Cirrhosis, Cardiovascular, And Metabolic Diseases - Latest Data Findings Released From TARGET-NASH Study
Read More
9/1/2020
EASL 2020: TARGET-NASH Oral Presentation & Abstract Poster Recap
Read More
8/28/2020
Target RWE Builds Growing COVID-19 Data Set of 70,000+ Patients, Announces Published Data Findings
Read More
8/24/2020
TARGET-NASH Expands to Europe, Enrolls First Participant
Read More
8/17/2020
TARGET-DERM Real-World Evidence Study Reaches 1,000 Enrolled Participants
Read More
5/7/2020
Novel Real-World Data Findings From Ongoing TARGET-IBD Study Published In DDW Proceedings
Read More
4/14/2020
TARGET-NASH Observational Study Reaches 5,000 Enrolled Patients
Read More
3/18/2020
COVID-19 Response
Read More
3/17/2020
TARGET PharmaSolutions Expands TARGET-DERM Research Community with Two New Industry Partnerships
Read More
3/13/2020
TARGET PharmaSolutions Launches Real-World Asthma Study
Read More
2/20/2020
TARGET-IBD Poster & Oral Presentation at ECCO
Read More
2/13/2020
TARGET PharmaSolutions Appoints Neal Bibeau as Chief Executive Officer
Read More
11/21/2019
TARGET-IBD Research Receives Presidential Poster Award And Outstanding Presenter Award At 2019 American College Of Gastroenterology Annual Scientific Meeting
Read More
8/15/2019
Executive Voice: She keeps the Triangle on target in life sciences
Read More
4/3/2019
2019 Women in Business Award!
Read More
2/27/2019
TARGET PharmaSolutions to Advance Dermatology Research, including Atopic Dermatitis, through New Collaboration
Read More
2/13/2019
TARGET PharmaSolutions Launches TARGET-DERM Real-World Observational Study to Advance the Understanding of Atopic Dermatitis (Eczema) and Other Immune-Mediated Inflammatory Skin Conditions
Read More
12/3/2018
TARGET PharmaSolutions Announces Partnership with Bristol Myers Squibb to Advance Inflammatory Bowel Disease (IBD) Research
Read More
11/20/2018
TARGET PharmaSolutions to Advance Research in NASH and Hepatitis B Through New Collaboration with Gilead Sciences
Read More
10/31/2018
TARGET PharmaSolutions Initiates a New Community, TARGET-HBV, to Advance the Understanding of Hepatitis B
Read More
1/10/2019
TARGET PharmaSolutions to advance NASH Research through new collaboration
Read More
10/20/2017
Why big pharma is partnering with this Chapel Hill data company - Triangle Business Journal
Read More
10/19/2017
Boehringer Ingelheim partners with TARGET PharmaSolutions to Progress NASH Research
Read More
10/19/2017
Intercept (ICPT) Extends Strategic Partnership with TARGET PharmaSolutions for TARGET-NASH
Read More
10/12/2017
Bristol-Myers Squibb (BMY) Extends Strategic Partnership with TARGET PharmaSolutions for TARGET-NASH
Read More
8/18/2017
Alumna Meg Powell Talks with Young Innovators about Clinical Trials
Read More
8/2/2017
TARGET PharmaSolutions Enrolls First Participant in its Inflammatory Bowel Disease (IBD) Community
Read More
4/20/2017
Allergan Partners with TARGET PharmaSolutions to Advance NASH Research
Read More
2/2/2017
TARGET PharmaSolutions Novel Clinical Data Model Helps Drug Industry
Read More
11/10/2016
TARGET PharmaSolutions Partners with Bristol-Myers Squibb, Offering a New Platform to Collect Real World Data
Read More
11/1/2016
Intercept Announces OCALIVA (OBETICHOLIC ACID) Data in PBC to be Presented at the 2016 AASLD Annual Meeting
Read More
Load More